Search research articles
Contact Us
Filters
Showing results (111-120 of 203) with videos related to
Page
of 21
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
January 4, 2008
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H Hofmann, Julia K Blievernicht, Kathrin Klein, et al.
Pharmacogenetics
|
March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
E U Griese, U M Zanger, U Brudermanns, et al.
Genome Medicine
|
January 15, 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
Anne T Nies, Mikko Niemi, Oliver Burk, et al.
The Histochemical Journal
|
January 5, 2002
Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours
J K Coller, P Fritz, U M Zanger, et al.
Clinical Pharmacology and Therapeutics
|
August 4, 2004
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects
Sebastian Raimundo, Claudia Toscano, Kathrin Klein, et al.
Pharmacogenomics
|
May 1, 2007
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
Markus Schirmer, Albert Rosenberger, Kathrin Klein, et al.
Biochimica Et Biophysica Acta
|
March 21, 2016
Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes
Benjamin A Kandel, Maria Thomas, Stefan Winter, et al.
Hepatology (Baltimore, Md.)
|
September 27, 2003
Sex is a major determinant of CYP3A4 expression in human liver
Renzo Wolbold, Kathrin Klein, Oliver Burk, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 18, 2003
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
Tanja Richter, Thomas E Mürdter, Georg Heinkele, et al.
Pharmacogenetics
|
September 30, 2003
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Julia Kirchheiner, Christian Klein, Ingolf Meineke, et al.
Page
of 21
Search research articles
Search
Showing results (111-120 of 203) with videos related to
Sort By:
Page
of 21
The Journal of Pharmacology and Experimental Therapeutics
|
January 4, 2008
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H Hofmann, Julia K Blievernicht, Kathrin Klein, et al.
Pharmacogenetics
|
March 25, 1998
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
E U Griese, U M Zanger, U Brudermanns, et al.
Genome Medicine
|
January 15, 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
Anne T Nies, Mikko Niemi, Oliver Burk, et al.
The Histochemical Journal
|
January 5, 2002
Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours
J K Coller, P Fritz, U M Zanger, et al.
Clinical Pharmacology and Therapeutics
|
August 4, 2004
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects
Sebastian Raimundo, Claudia Toscano, Kathrin Klein, et al.
Pharmacogenomics
|
May 1, 2007
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
Markus Schirmer, Albert Rosenberger, Kathrin Klein, et al.
Biochimica Et Biophysica Acta
|
March 21, 2016
Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes
Benjamin A Kandel, Maria Thomas, Stefan Winter, et al.
Hepatology (Baltimore, Md.)
|
September 27, 2003
Sex is a major determinant of CYP3A4 expression in human liver
Renzo Wolbold, Kathrin Klein, Oliver Burk, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 18, 2003
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine
Tanja Richter, Thomas E Mürdter, Georg Heinkele, et al.
Pharmacogenetics
|
September 30, 2003
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Julia Kirchheiner, Christian Klein, Ingolf Meineke, et al.
Page
of 21